Biosimilars and Their Use in Cancer Treatment
On today's episode, we are thrilled to discuss an important and often misunderstood area of oncology- biosimilars and their increasing use in cancer care.
You might be curious, what exactly are biosimilars? How are they developed and approved? And most importantly, how are they transforming the lives of patients diagnosed with cancer?
We will break down these questions and more as we explore this with an overview from Dr. Julie Gralow, a breast medical oncologist and chief medical officer at the American Society of Clinical Oncology.
Meet the Guest of the Episode
Julie Gralow, MD, FACP, FASCO|ASCO
Dr. Gralow is the Chief Medical Office and Executive Vice President of American Society of Clinical Oncologists (ASCO). She is a breast medical oncologist and Professor (emeritus) of Medical Oncology and adjunct Professor of Global Health at the University of Washington School of Medicine. Dr. Gralow is the former Executive Officer for Breast and Lung Cancer and Vice Chair of the Breast Cancer Committee for the SWOG Cancer Clinical Trials Network. She is committed to improving quality of life for patients with cancer, and is co-Founder of Team Survivor Northwest, a non-profit aimed at helping female cancer survivors improve their health through fitness and exercise, and the Women’s Empowerment Cancer Advocacy Network (WE CAN) to support cancer advocacy and education in low- and middle-income countries.
